Cantor Fitzgerald Weighs in on Mesoblast FY2025 Earnings

Mesoblast Limited (NASDAQ:MESO) – Investment analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for Mesoblast in a note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst L. Chen anticipates that the company will post earnings per share of ($0.70) for the year. The consensus estimate for Mesoblast’s current full-year earnings is ($0.72) per share.

A number of other equities research analysts have also commented on MESO. Jefferies Financial Group lowered shares of Mesoblast from a “buy” rating to a “hold” rating in a report on Monday, December 23rd. Piper Sandler boosted their price target on Mesoblast from $11.00 to $15.00 and gave the company an “overweight” rating in a report on Thursday, December 19th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $13.50.

Mesoblast Price Performance

NASDAQ MESO opened at $18.27 on Thursday. The company has a debt-to-equity ratio of 0.21, a current ratio of 1.18 and a quick ratio of 1.18. The business has a 50 day simple moving average of $14.81 and a 200 day simple moving average of $10.18. Mesoblast has a 52-week low of $1.75 and a 52-week high of $22.00.

Institutional Investors Weigh In On Mesoblast

Hedge funds and other institutional investors have recently made changes to their positions in the business. Marshall Wace LLP acquired a new stake in shares of Mesoblast during the 2nd quarter worth approximately $562,000. XY Capital Ltd bought a new stake in Mesoblast during the third quarter worth $244,000. Jane Street Group LLC lifted its stake in Mesoblast by 46.4% during the third quarter. Jane Street Group LLC now owns 85,102 shares of the company’s stock worth $695,000 after purchasing an additional 26,959 shares during the last quarter. Creative Planning acquired a new stake in shares of Mesoblast in the 3rd quarter valued at $147,000. Finally, XTX Topco Ltd bought a new position in shares of Mesoblast in the 2nd quarter valued at $103,000. 1.43% of the stock is currently owned by institutional investors and hedge funds.

Mesoblast Company Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.